DK2046373T3 - Krystalliseret oxalatdecarboxylase og fremgangsmåder til anvendelse - Google Patents

Krystalliseret oxalatdecarboxylase og fremgangsmåder til anvendelse

Info

Publication number
DK2046373T3
DK2046373T3 DK07873799.6T DK07873799T DK2046373T3 DK 2046373 T3 DK2046373 T3 DK 2046373T3 DK 07873799 T DK07873799 T DK 07873799T DK 2046373 T3 DK2046373 T3 DK 2046373T3
Authority
DK
Denmark
Prior art keywords
methods
oxalate decarboxylase
crystallized
crystallized oxalate
decarboxylase
Prior art date
Application number
DK07873799.6T
Other languages
English (en)
Inventor
Bhami C Shenoy
Teresa G Cachero
Lekai Zhang
Aftab Rashid
Danica Grujic
Reena Patel
Margaret Ellen Mcgrath
John Shin
Original Assignee
Althea Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Althea Technologies Inc filed Critical Althea Technologies Inc
Application granted granted Critical
Publication of DK2046373T3 publication Critical patent/DK2046373T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/75—General characteristics of the apparatus with filters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
DK07873799.6T 2006-08-02 2007-08-02 Krystalliseret oxalatdecarboxylase og fremgangsmåder til anvendelse DK2046373T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83493306P 2006-08-02 2006-08-02
US85454006P 2006-10-26 2006-10-26
PCT/US2007/075091 WO2008105911A2 (en) 2006-08-02 2007-08-02 Crystallized oxalate decarboxylase and methods of use

Publications (1)

Publication Number Publication Date
DK2046373T3 true DK2046373T3 (da) 2013-05-27

Family

ID=39721749

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07873799.6T DK2046373T3 (da) 2006-08-02 2007-08-02 Krystalliseret oxalatdecarboxylase og fremgangsmåder til anvendelse

Country Status (12)

Country Link
US (8) US8142775B2 (da)
EP (1) EP2046373B1 (da)
JP (1) JP2009545622A (da)
CN (1) CN103272225B (da)
AU (1) AU2007347695A1 (da)
CA (1) CA2659081C (da)
DK (1) DK2046373T3 (da)
ES (1) ES2412254T3 (da)
IL (1) IL196777A0 (da)
PT (1) PT2046373E (da)
RU (1) RU2009107184A (da)
WO (1) WO2008105911A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
ES2362897T3 (es) 2005-12-16 2011-07-14 Oxthera, Inc. Composiciones y métodos para reducción del oxalato.
EP2046373B1 (en) 2006-08-02 2013-03-20 Althea Technologies, Inc. Crystallized oxalate decarboxylase and methods of use
CA3012811A1 (en) * 2009-07-02 2011-01-06 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
DK2270138T3 (da) 2009-07-02 2018-06-25 Oxthera Intellectual Property Ab Oprensning og isolering af rekombinante oxalat-nedbrydende enzymer
CA2781712A1 (en) * 2009-11-25 2011-06-03 Captozyme, Llc Methods and compositions for treating oxalate-related conditions
US9714456B2 (en) 2013-01-18 2017-07-25 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
US11077238B2 (en) 2013-06-07 2021-08-03 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
JOP20200118A1 (ar) * 2013-07-05 2017-06-16 Oxthera Intellectual Property Ab مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس
CN103614359B (zh) * 2013-11-27 2015-12-02 南宁奕德环境科技有限公司 一种单甲氧基聚乙二醇修饰草酸脱羧酶的方法
KR20180044225A (ko) * 2015-04-02 2018-05-02 캡토자임, 엘엘씨 불용성 및 가용성의 옥살레이트의 분해를 위한 고효율의 옥살레이트 분해 효소
CN107868775A (zh) 2016-09-23 2018-04-03 武汉康复得生物科技股份有限公司 草酸脱羧酶的制备及其制品和应用
CN108588060B (zh) * 2017-03-07 2020-12-01 武汉康复得生物科技股份有限公司 一种用丝状真菌宿主细胞表达的重组草酸脱羧酶
CA3099266A1 (en) * 2018-05-08 2019-11-14 Yale University Compositions and methods for reducing progression of nephrolithiasis
WO2021092472A1 (en) * 2019-11-06 2021-05-14 Allena Pharmaceuticals, Inc. Methods of treating hyperoxaluria
CN112076359B (zh) * 2020-09-14 2022-10-28 江苏恰瑞生物科技有限公司 用于肾结石治疗的血浆吸附过滤装置及其过滤方法
WO2022140538A1 (en) * 2020-12-23 2022-06-30 Massachusetts Institute Of Technology Modified bacterium for oxalate degradation and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
US5756090A (en) 1991-02-21 1998-05-26 Eoe, Inc. Oxygen activatable formulations for disinfection or sterilization
RO114979B1 (ro) 1991-02-25 1999-09-30 Ici Plc Oxalat oxidaza avand capacitatea de a degrada acidul oxalic si procedeu pentru obtinerea oxalat oxidazei in plante
US6229065B1 (en) 1991-03-05 2001-05-08 Rhone-Poulenc Agrochimie Production of plants resistant to attacks by Sclerotinia sclerotiorum by the introduction of a gene encoding an oxalate oxidase
DE69219686T2 (de) 1991-07-29 1997-09-11 Mochida Pharm Co Ltd Verfahren und Vorrichtung zur Verwendung in spezifischen Bindungstests
US6140475A (en) 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
JP2005537037A (ja) * 2001-10-05 2005-12-08 イクシオン・バイオテクノロジー・インコーポレーテッド 流体の蓚酸塩濃度を減少させる物質および方法
US6929940B1 (en) * 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
WO2004018634A2 (en) 2002-08-20 2004-03-04 University Of Florida Polynucleotide encoding oxalate decarboxylase from aspergillus niger and methods of use
US20050232901A1 (en) * 2004-04-14 2005-10-20 Zaghmout Ousama M Materials and methods for treating or preventing oxalate-related disease
JP5199077B2 (ja) * 2005-06-10 2013-05-15 アルタス ファーマシューティカルズ インコーポレイテッド シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法
WO2007070052A2 (en) 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
ES2362897T3 (es) 2005-12-16 2011-07-14 Oxthera, Inc. Composiciones y métodos para reducción del oxalato.
JP2008010106A (ja) * 2006-06-30 2008-01-17 Toshiba Corp 記録装置，および記録方法
EP2046373B1 (en) 2006-08-02 2013-03-20 Althea Technologies, Inc. Crystallized oxalate decarboxylase and methods of use
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
CA2781712A1 (en) 2009-11-25 2011-06-03 Captozyme, Llc Methods and compositions for treating oxalate-related conditions
US9714456B2 (en) 2013-01-18 2017-07-25 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
US11077238B2 (en) 2013-06-07 2021-08-03 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis

Also Published As

Publication number Publication date
CA2659081C (en) 2018-01-16
US20180250371A1 (en) 2018-09-06
US8741284B2 (en) 2014-06-03
US20200129599A1 (en) 2020-04-30
PT2046373E (pt) 2013-05-06
US20150004204A1 (en) 2015-01-01
CA2659081A1 (en) 2008-09-04
US9821041B2 (en) 2017-11-21
RU2009107184A (ru) 2010-09-10
US8142775B2 (en) 2012-03-27
US20160051647A1 (en) 2016-02-25
EP2046373A2 (en) 2009-04-15
EP2046373B1 (en) 2013-03-20
US10369203B2 (en) 2019-08-06
IL196777A0 (en) 2011-08-01
US20220133865A1 (en) 2022-05-05
ES2412254T3 (es) 2013-07-10
JP2009545622A (ja) 2009-12-24
AU2007347695A1 (en) 2008-09-04
US9155785B2 (en) 2015-10-13
US20180214522A1 (en) 2018-08-02
CN103272225A (zh) 2013-09-04
WO2008105911A2 (en) 2008-09-04
WO2008105911A3 (en) 2008-10-16
US20120308545A1 (en) 2012-12-06
EP2046373A4 (en) 2010-04-14
CN103272225B (zh) 2018-05-22
US20080038246A1 (en) 2008-02-14
WO2008105911A9 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
DK2046373T3 (da) Krystalliseret oxalatdecarboxylase og fremgangsmåder til anvendelse
DK2099447T3 (da) Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
DK2147315T3 (da) Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
DK2121614T3 (da) Aminonikotin og isonikotinsyrederivater som dhodh-inhibitorer
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DK1924577T3 (da) Substituerede benzimidazoler og fremgangsmåder til fremstilling
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
DK2439205T3 (da) Carboxamidforbindelser og deres anvendelse som calpaininhibitorer
DK2379096T3 (da) TFPI-inhibitorer og fremgangsmåder til anvendelse
BRPI0807225A2 (pt) Dispositivo e método endocirúrgico
NO20064164L (no) Fremgangsmate og anordning for dynamisk streaming-/arkiveringskonfigurasjon
DK2222675T3 (da) 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
NO20076678L (no) Glutamataggrekanaseinhibitorer
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
BRPI0816907A2 (pt) Método e dispositivo
DK2038275T3 (da) Ny pyridazinforbindelse og anvendelse heraf
DK2019090T3 (da) Substitueret beta-phenyl-alfa-hydroxypropansyre, fremgangsmåde til syntese og anvendelse deraf
DK1937276T3 (da) Forbedret testosterongel og fremgangsmåde til anvendelse deraf
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK2099796T3 (da) Aza-indolyl-forbindelser og fremgangsmåder for anvendelse
DK2107373T3 (da) Analysechip og analysefremgangsmåde
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
EP2373658A4 (en) STAT3 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME